TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 22409644
Drug: Cognitive-behavioral therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral therapy (CBT) for 10 weeks, supplemented with up to 4 caregiver educational sessions.
Study: 15956632
Drug: Orlistat (120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orlistat (120 mg, 3 times daily for 1 year)
Study: 15956632
Drug: Placebo (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (3 times daily for 1 year)
Study: 10579613
Drug: Goserelin acetate
Normalized name: Goserelin Acetate
DrugBank: Goserelin (DB00014)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Goserelin acetate (3.6 mg depot once every 28 days for four months, followed by additional cycles if menorrhagia occurred)
Study: 1931534
Drug: Bioavail slow-release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bioavail slow-release theophylline capsule
Study: 24289920
Drug: Eculizumab (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eculizumab (600 mg weekly for 4 weeks followed by 900 mg every 2 weeks until week 24; or 900 mg weekly for 4 weeks followed by 1200 mg every 2 weeks until week 24)
Study: 22344966
Drug: Vitamin D3-fortified
Normalized name: vitamin D3
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D3-fortified doogh (FD; 500 IU/250 mL, n=50)
Study: 22344966
Drug: Plain doogh
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plain doogh (PD; no detectable vitamin D/250 mL, n=50)
Study: 19568826
Drug: Atomoxetine (1.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atomoxetine (1.4 mg/kg mean final dose)
Study: 15970067
Drug: Doxazosin (1-8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxazosin (1-8 mg)
Study: 15970067
Drug: Bendrofluazide (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bendrofluazide (2.5 mg)
Study: 8880057
Drug: Orlistat 50
Normalized name: Orlistat
DrugBank: Orlistat (DB01083)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Orlistat 50 mg 3 times daily for 7 or 8 days
Study: 6150771
Drug: Insulin plus
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin plus saline
Study: 6150771
Drug: Insulin plus
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin plus cimetidine
Study: 6150771
Drug: Insulin plus
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin plus dextrose
Study: 24195949
Drug: Intrathecal SP‐SAP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal SP‐SAP (20‐60 ?g) in addition to standard‐of‐care analgesic therapy
Study: 24195949
Drug: Standard‐of‐care analgesic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard‐of‐care analgesic therapy alone (control)
Study: 21626017
Drug: LED therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: LED therapy (GaAlAs, 640 nm, 4 J/cm(2), 0.10 W, 70 s)
Study: 21626017
Drug: Laser therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Laser therapy (InGaAlP, 660 nm, 4 J/cm(2), 0.03 W, 25 s)
Study: 18633599
Drug: Polidocanol 5
Normalized name: polidocanol 5 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polidocanol 5 mg/ml (group A)
Study: 18633599
Drug: Polidocanol 10
Normalized name: polidocanol 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polidocanol 10 mg/ml (group B)
Study: 18633599
Drug: Polidocanol 10
Normalized name: polidocanol 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polidocanol 10 mg/ml (additional treatment for unsatisfied patients)
Study: 9038459
Drug: Ondansetron 8
Normalized name: ondansetron 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ondansetron 8 mg intravenously
Study: 16418023
Drug: Meperidine 0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meperidine 0.4 mg/kg intravenously
Study: 9126713
Drug: Cognitive-existential group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-existential group therapy integrated over 6 months with adjuvant chemotherapy.
Study: 9126713
Drug: Cognitive-existential group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-existential group therapy
Study: 2876741
Drug: Somatostatin infusion
Normalized name: somatostatin
DrugBank: Somatostatin (DB09099)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Somatostatin infusion (250 micrograms/h continuously during 120 h)
Study: 2876741
Drug: Cimetidine (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine (200 mg IV every 4 h for 5 days) and pirenzepine (10 mg IV every 8 h for 5 days)
Study: 31602530
Drug: Thresholds for
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thresholds for diagnosing IT success at 6 months post-transplant: SD at 22.76 mg/dL (sensitivity 88.89%, specificity 80.00%); CV at 17.47% (sensitivity 88.89%, specificity 70.00%); MAGE at 54.81 mg/dL (sensitivity 88.89%, specificity 80.00%); GVP at 12.27% (sensitivity 88.89%, specificity 70.00%).
Study: 29422651
Drug: Dual-hormone closed-loop
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual-hormone closed-loop system (DH-CLS) with simplified meal bolus approach for 75g carbohydrate meal
Study: 29422651
Drug: Dual-hormone closed-loop
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual-hormone closed-loop system (DH-CLS) with simplified meal bolus approach for 45g carbohydrate meal
Study: 29422651
Drug: Overestimated meal
Normalized name: bone meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overestimated meal insulin bolus for 75g carbohydrate meal
Study: 29422651
Drug: Overestimated meal
Normalized name: bone meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overestimated meal insulin bolus for 45g carbohydrate meal
Study: 29422651
Drug: Dual-hormone closed-loop
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual-hormone closed-loop system (DH-CLS) with simplified meal bolus approach
Study: 18690349
Drug: Antithrombin (AT)
Normalized name: antithrombin III
DrugBank: Antithrombin gamma (DB16094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antithrombin (AT) administration for four consecutive days after thermal injury
Study: 18690349
Drug: Non-antithrombin (non-AT)
Normalized name: antithrombin III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-antithrombin (non-AT) treatment
Study: 15978306
Drug: Valsartan 160
Normalized name: valsartan 160 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valsartan 160 mg plus HCTZ 12.5 mg OD
Study: 15978306
Drug: Valsartan 160
Normalized name: valsartan 160 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valsartan 160 mg plus HCTZ 25 mg OD
Study: 15978306
Drug: Amlodipine 10
Normalized name: amlodipine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amlodipine 10 mg OD
Study: 8992964
Drug: 125 mg
Normalized name: niacin 125 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 125 mg paracetamol suppository
Study: 8992964
Drug: 250 mg
Normalized name: rutin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mg paracetamol suppository
Study: 8992964
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg cut-in-half paracetamol tablet
Study: 6104935
Drug: Lorazepam 2.5
Normalized name: lorazepam 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lorazepam 2.5 mg orally at 2200 h and 0800 h
Study: 6104935
Drug: Diazepam 10
Normalized name: diazepam 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazepam 10 mg orally at the same times
Study: 6104935
Drug: Lorazepam 2.5
Normalized name: lorazepam 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lorazepam 2.5 mg orally
Study: 7034755
Drug: Diazepam 10
Normalized name: diazepam 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazepam 10 mg orally
Study: 15497662
Drug: Test formulation
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test formulation (Kolestor)
Study: 9481974
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg diazepam intravenously
Study: 2188410
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg diazepam rectally
Study: 9481974
Drug: 35 mg
Normalized name: papain 35 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 35 mg diazepam rectally
Study: 30184543
Drug: Biweekly cetuximab
Normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Biweekly cetuximab (500 mg/m2)
Study: 30184543
Drug: Weekly cetuximab
Normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Weekly cetuximab (250 mg/m2)
Study: 22809163
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment protocol (TP)
Study: 22276821
Drug: Docetaxel (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Docetaxel (100 mg/m² on day 1)
Study: 22276821
Drug: Docetaxel (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Docetaxel (75 mg/m² on day 1) + Capecitabine (825 mg/m² twice a day on days 1 to 14)
Study: 22276821
Drug: Docetaxel (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Docetaxel (75 mg/m² on day 1) + Gemcitabine (1000 mg/m² on days 1 and 8)
Study: 22276821
Drug: Bevacizumab (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bevacizumab (15 mg/kg for the first six cycles of chemotherapy)
Study: 20858863
Drug: Creatinine (>90
Approvals — FDA: no, EMA: no, PMDA: no
Description: Creatinine (>90 μmol/L)
Study: 15848695
Drug: Thymoglobulin, sirolimus,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thymoglobulin, sirolimus, reduced-dose cyclosporine, and corticosteroids
Study: 12088164
Drug: Ziprasidone, 80-160
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ziprasidone, 80-160 mg/day (N = 148)
Study: 12088164
Drug: Haloperidol, 5-15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Haloperidol, 5-15 mg/day (N = 153)
Study: 2221488
Drug: Quazolast, 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quazolast, 400 mg bid orally
Study: 74533
Drug: Concentrated dietary
Normalized name: sodium phosphate, monobasic
DrugBank: Sodium phosphate, monobasic (DB09449)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Concentrated dietary fibre from bran (20 g/day)
Study: 74533
Drug: Concentrated dietary
Normalized name: sodium phosphate, monobasic
DrugBank: Sodium phosphate, monobasic (DB09449)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Concentrated dietary fibre from cabbage (20 g/day)
Study: 74533
Drug: Concentrated dietary
Normalized name: sodium phosphate, monobasic
DrugBank: Sodium phosphate, monobasic (DB09449)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Concentrated dietary fibre from carrot (20 g/day)
Study: 74533
Drug: Concentrated dietary
Normalized name: sodium phosphate, monobasic
DrugBank: Sodium phosphate, monobasic (DB09449)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Concentrated dietary fibre from apple (20 g/day)
Study: 74533
Drug: Concentrated dietary
Normalized name: sodium phosphate, monobasic
DrugBank: Sodium phosphate, monobasic (DB09449)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Concentrated dietary fibre from guar gum (20 g/day)
Study: 30457436
Drug: HDC vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HDC vaccine (HDCV)
Study: 30457436
Drug: Hamster kidney
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hamster kidney cell vaccine
Study: 21338892
Drug: Random laboratory
Normalized name: jojoba oil, randomized
Approvals — FDA: no, EMA: no, PMDA: no
Description: Random laboratory drug testing program (PDT)
Study: 19149760
Drug: Chemotherapy or
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy or EGFR inhibitors
Study: 19149760
Drug: New EGFR
Approvals — FDA: no, EMA: no, PMDA: no
Description: New EGFR inhibitors
Study: 15202617
Drug: Antihypertensive treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antihypertensive treatment (specifics not provided)
Study: 11229673
Drug: Intratumoral injection
Normalized name: bimatoprost
DrugBank: Bimatoprost (DB00905)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Intratumoral injection of HSV1716 (10^3 plaque-forming units)
Study: 25638740
Drug: Dexmedetomidine (DEX)
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexmedetomidine (DEX) 1.2mcg/kg/hour (high dose)
Study: 25638740
Drug: Dexmedetomidine (DEX)
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexmedetomidine (DEX) 0.4mcg/kg/hour (low dose)
Study: 19138934
Drug: Intervention group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intervention group (smokers with oral tissue methylation)
Study: 19138934
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (smokers without oral tissue methylation)
Study: 19138934
Drug: Baseline methylation
Normalized name: methylal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baseline methylation for p16 in oral tissue
Study: 19138934
Drug: Baseline methylation
Normalized name: methylal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baseline methylation for FHIT in oral tissue
Study: 19138934
Drug: Baseline methylation
Normalized name: methylal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baseline methylation for both p16 and FHIT in oral tissue
Study: 19138934
Drug: Correlation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Correlation of methylation patterns between oral and bronchial tissues
Study: 15258349
Drug: Ticlopidine (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ticlopidine (500 mg/d)
Study: 1543449
Drug: Aspirin (650
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (650 mg/d)
Study: 11795342
Drug: Tamoxifen (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamoxifen (20 mg/day) for up to 8 years
Study: 28694471
Drug: 2% doxycycline
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% doxycycline solution
Study: 25867446
Drug: Cognitive-behavioral therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral therapy guided self-help (CBTgsh)
Study: 25867446
Drug: Cognitive-behavioral therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral therapy guided self-help (CBTgsh) and Interpersonal psychotherapy (IPT)
Study: 20196109
Drug: DBT‐AF (appetite
Approvals — FDA: no, EMA: no, PMDA: no
Description: DBT‐AF (appetite focused dialectical behavior therapy)
Study: 19708562
Drug: Transcranial electrotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transcranial electrotherapy using a TRANSAIR‐02 apparatus (combined with traditional treatment)
Study: 14571451
Drug: Fluoride gel
Normalized name: Sodium Fluoride Gel
DrugBank: Sodium fluorophosphate (DB09484)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoride gel treatment (EF group)
Study: 14571451
Drug: Fluoride gel
Normalized name: Sodium Fluoride Gel
DrugBank: Sodium fluorophosphate (DB09484)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoride gel treatment followed by argon laser irradiation (EFL group)
Study: 14571451
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment (E group)
Study: 10594469
Drug: Doxazosin GITS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxazosin GITS 4 mg once daily
Study: 10594469
Drug: Doxazosin standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxazosin standard (1 mg day-1 titrated to higher dose)
Study: 10594469
Drug: Doxazosin GITS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxazosin GITS 4 mg and 8 mg
Study: 10594469
Drug: Doxazosin GITS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxazosin GITS once daily for 7 days
Study: 6762670
Drug: Manipulation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manipulation of the cervical spine with an amnesic dose of diazepam
Study: 6421359
Drug: Hepatitis B
Normalized name: HEPATITIS B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hepatitis B vaccine (10 micrograms) given at 0, 1, and 2 months of age
Study: 6421359
Drug: Hepatitis B
Normalized name: HEPATITIS B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hepatitis B vaccine (10 micrograms) given at 3, 4, and 5 months of age
Study: 27276421
Drug: Deferiprone (DFP)
Normalized name: Deferiprone
DrugBank: Deferiprone (DB08826)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Deferiprone (DFP) 33 mg kg(‐1) single oral dose
Study: 27276421
Drug: Deferiprone 3‐O‐glucuronide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deferiprone 3‐O‐glucuronide (DFP‐G)
Study: 23383461
Drug: Acupuncture therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture therapy (true acupuncture needles), treated once every other day for 12 sessions
Study: 23383461
Drug: Acupuncture therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture therapy (true acupuncture needles)
Study: 20655809
Drug: NGX-4010 (8%
Approvals — FDA: no, EMA: no, PMDA: no
Description: NGX-4010 (8% capsaicin patch) for 30 minutes
Study: 20655809
Drug: NGX-4010 (8%
Approvals — FDA: no, EMA: no, PMDA: no
Description: NGX-4010 (8% capsaicin patch) for 60 minutes
Study: 20655809
Drug: NGX-4010 (8%
Approvals — FDA: no, EMA: no, PMDA: no
Description: NGX-4010 (8% capsaicin patch) for 90 minutes
Study: 20655809
Drug: Pooled control
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pooled control group (0.04% capsaicin patch)
Study: 18841250
Drug: Difluoromethylornithine (DFMO)
Normalized name: α-difluoromethylornithine
DrugBank: Eflornithine (DB06243)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Difluoromethylornithine (DFMO) 500 mg and sulindac 150 mg once daily
Study: 15901456
Drug: GIII series
Normalized name: triclosan
DrugBank: Triclosan (DB08604)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GIII series sequential media
Study: 12525796
Drug: PYC (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: PYC (200 mg/day)
Study: 2870876
Drug: 1.0 mg
Normalized name: HYDROCORTISONE BUTYRATE 1.0 mg in 1 g TOPICAL CREAM
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0 mg loprazolam
Study: 6142463
Drug: 5.0 mg
Normalized name: RUXOLITINIB 5.0 mg ORAL TABLET [JAKAFI]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5.0 mg nitrazepam
Study: 12022239
Drug: Irbesartan (AT1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Irbesartan (AT1 receptor antagonist)
Study: 12022239
Drug: Atenolol (beta1-adrenergic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atenolol (beta1-adrenergic receptor blocker)
Study: 7491227
Drug: Oxandrolone (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxandrolone (0.1 mg/kg daily for 1 year)
Study: 1780618
Drug: PGE2 administration
Normalized name: PGE2
DrugBank: Dinoprostone (DB00917)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: PGE2 administration for cervical maturation
Study: 7039244
Drug: Continuous heparin
Normalized name: Uniphyllin Continus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous heparin treatment
Study: 7039244
Drug: Intermittent heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent heparin treatment
Study: 7039244
Drug: Both continuous
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both continuous and intermittent heparin treatment
Study: 31661346
Drug: Integrated Psychological
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Integrated Psychological Therapy (IPT)
Study: 30346226
Drug: Standard Treatment
Normalized name: Azo-Standard
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Standard Treatment (TAU)
Study: 23134272
Drug: Music therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Music therapy and guided visual imagery
Study: 16675324
Drug: Beta-agonist asthma
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-agonist asthma control scale derived from administrative data
Study: 16675324
Drug: Beta-agonist asthma
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-agonist asthma control scale
Study: 15327427
Drug: SSFP without
Normalized name: threonine
DrugBank: Threonine (DB00156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: SSFP without magnetization preparation
Study: 10903238
Drug: Continuous group
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous group (maintenance prednisone dose for 6 months)
Study: 10903238
Drug: Demand group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Demand group (withdrawn from prednisone at a rate of 5 mg per week)
Study: 8161669
Drug: Lansoprazole 30
Normalized name: lansoprazole 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lansoprazole 30 mg/day for 7 days
Study: 3531309
Drug: Ranitidine 150
Normalized name: ranitidine 150 MG
DrugBank: Ranitidine (DB00863)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ranitidine 150 mg twice daily (b.i.d.)
Study: 22698700
Drug: 400 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 μg of misoprostol
Study: 19833454
Drug: sublingual 200microg
Approvals — FDA: no, EMA: no, PMDA: no
Description: sublingual 200microg misoprostol with 20UI intravenous oxytocin
Study: 19833454
Drug: only oxytocin
Normalized name: Product containing only oxytocin (medicinal product)
Approvals — FDA: no, EMA: no, PMDA: no
Description: only oxytocin at the same dose
Study: 16706761
Drug: Control treatment
Normalized name: SALICYLIC ACID 190 mg in 1 mL TOPICAL LIQUID [Derma E Acne Blemish Control Treatment Serum]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control treatment (Fucidine cream with Cutiplast sterile dressing)
Study: 11305006
Drug: Intravenous immunoglobulin
Normalized name: Intravenous immunoglobulin (IVIg)
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous immunoglobulin (5 g administered for 3 days)
Study: 326237
Drug: 3% vancomycin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3% vancomycin gel applied topically using pre-trimmed plastic trays for 5 minutes every morning in school.
Study: 326237
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no vancomycin treatment).
Study: 24372884
Drug: Explicit speech
Normalized name: Empliciti
DrugBank: Elotuzumab (DB06317)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Explicit speech and language therapy with visual support (Shape Coding)
Study: 24372884
Drug: Waiting controls
Normalized name: White Petrolatum
DrugBank: Petrolatum (DB11058)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Waiting controls (no therapy during Phase 1)
Study: 24372884
Drug: Waiting controls
Normalized name: White Petrolatum
DrugBank: Petrolatum (DB11058)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Waiting controls (after receiving therapy in Phase 2)
Study: 24372884
Drug: Combined groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined groups (therapy and waiting controls)